Key Events This Week
29 Jun: New 52-week high at Rs.2,766 and all-time high at Rs.2,749.95
30 Jun: New 52-week high at Rs.2,825 and all-time high at Rs.2,824.95
1 Jul: New 52-week high at Rs.2,868.95 and all-time high at Rs.2,850
3 Jul: Sharp decline to Rs.2,588.80 (-6.16%) on heavy volume
29 June 2026: New 52-Week and All-Time Highs Spark Optimism
Fredun Pharmaceuticals Ltd began the week on a strong note, hitting a new 52-week high of Rs.2,766 and an all-time high of Rs.2,749.95 on 29 June 2026. The stock closed at Rs.2,735.60, up 2.99% for the day, significantly outperforming the Sensex, which was nearly flat at 35,960.98. This marked the third consecutive day of gains, with the stock appreciating over 10.8% in this period. The rally was supported by robust financial metrics, including a 37.57% year-on-year increase in net sales and an 87.64% rise in profit after tax for the nine months ended March 2026. Promoter confidence was evident as their stake rose by 1.11% to 44.17%, reinforcing positive sentiment.
30 June 2026: Momentum Continues with Fresh Highs Amid Market Volatility
The bullish momentum extended into 30 June, with Fredun Pharmaceuticals reaching a new 52-week high of Rs.2,825 and an all-time high of Rs.2,824.95. The stock gained 2.90% on the day, closing at Rs.2,814.30, while the Sensex declined marginally by 0.01%. This outperformance was notable given the broader market weakness, with technology indices hitting new lows. Technical indicators remained strongly bullish, with the stock trading above all key moving averages and supported by positive MACD and Bollinger Bands signals. The company’s Mojo Score of 71.0 and upgraded Mojo Grade to Buy further underscored its improving fundamentals.
Handpicked from 50, scrutinized by experts – Our recent selection, this Mid Cap from Bank - Public, is already delivering results. Don't miss next month's pick!
- - Expert-scrutinized selection
- - Already delivering results
- - Monthly focused approach
1 July 2026: New Highs Amid Sustained Buying Interest
On 1 July, Fredun Pharmaceuticals Ltd continued its upward trajectory, touching a new 52-week high of Rs.2,868.95 and an all-time high of Rs.2,850. The stock closed at Rs.2,805.45, up 1.84%, outperforming the Sensex’s modest 0.34% gain. This marked five consecutive days of gains, delivering a cumulative return of 14.61%. The company’s strong quarterly results, including a record quarterly PAT of Rs.10.78 crores and a 54.96% increase in profit before tax (excluding other income), supported the rally. Technical indicators remained bullish, with the stock trading comfortably above all major moving averages and positive momentum signals from MACD and KST.
2 July 2026: Early Signs of Profit Taking Amid Market Strength
Fredun Pharmaceuticals faced a setback on 2 July, closing at Rs.2,758.80, down 1.66% on the day. This decline came despite the Sensex gaining 0.71%, indicating some profit-taking pressure on the stock after its recent rally. Volume increased slightly to 9,720 shares, suggesting cautious investor behaviour. The stock remained above key moving averages, but the dip hinted at a potential consolidation phase following the strong gains earlier in the week.
3 July 2026: Sharp Decline on Heavy Volume Signals Caution
The week ended with a sharp sell-off on 3 July, as Fredun Pharmaceuticals plunged 6.16% to close at Rs.2,588.80 on heavy volume of 31,132 shares. This decline contrasted with the Sensex’s modest 0.15% gain, highlighting a significant divergence. The steep fall erased much of the week’s earlier gains and raised questions about near-term momentum. The heavy volume suggests institutional or large investor selling, possibly triggered by valuation concerns or short-term profit booking. Despite this, the stock’s long-term fundamentals and promoter confidence remain intact, though the immediate technical outlook has weakened.
Want to dive deeper on Fredun Pharmaceuticals Ltd? There's a real-time research report diving right into the fundamentals, valuations, peer comparison, financials, technicals and much more!
- - Real-time research report
- - Complete fundamental analysis
- - Peer comparison included
Weekly Price Performance: Fredun Pharmaceuticals Ltd vs Sensex
| Date | Stock Price | Day Change | Sensex | Day Change |
|---|---|---|---|---|
| 2026-06-29 | Rs.2,735.60 | +2.99% | 35,960.98 | – |
| 2026-06-30 | Rs.2,814.30 | +2.88% | 35,958.71 | -0.01% |
| 2026-07-01 | Rs.2,805.45 | -0.31% | 36,119.01 | +0.45% |
| 2026-07-02 | Rs.2,758.80 | -1.66% | 36,376.02 | +0.71% |
| 2026-07-03 | Rs.2,588.80 | -6.16% | 36,431.45 | +0.15% |
Key Takeaways
Positive Signals: The week began with strong momentum as Fredun Pharmaceuticals Ltd set multiple new 52-week and all-time highs, supported by robust financial growth, including a 37.57% increase in net sales and an 87.64% rise in PAT over nine months. Promoter confidence strengthened with a 1.11% increase in shareholding, and technical indicators remained bullish through the first half of the week.
Cautionary Signals: The sharp 6.16% decline on 3 July on heavy volume signals potential profit booking or institutional selling, raising concerns about short-term momentum. The stock underperformed the Sensex by 6.68% over the week, and the divergence from broader market gains suggests increased volatility. Investors should monitor volume trends and technical support levels closely in the coming sessions.
Conclusion
Fredun Pharmaceuticals Ltd’s week was a tale of two halves: an impressive rally through the first three trading days, marked by record highs and strong fundamentals, followed by a steep correction on the final day. While the company’s underlying financial strength and promoter confidence remain intact, the recent sell-off highlights the importance of cautious monitoring amid valuation pressures and market volatility. The stock’s ability to sustain its technical momentum and recover from the sharp decline will be critical in determining its near-term trajectory within the Pharmaceuticals & Biotechnology sector.
Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →
